Recent Business Highlights

Healthy Pipeline of First-to-market, Tough-to-make Products Bringing Expensive Medicine within Reach NUMBER OF PENDING FILINGS* BY DOSAGE FORM Topical/ Transdermal/ Vaginal, 9 Inhalation, 2 Softgel, 2 Complex Inj/ Sterile, 20 Inj, 16 Filings as of March 31, 2018; Internal estimates Complex OSD, 22 OSD, 39 PIPELINE HIGHLIGHTS 107 pending ANDAS & 3 pending NDAs (505b2s) • No incl. 63 para-IV and 30 first to file products Portfolio of products based on: . Complex Characterization / Analytical chemistry • Novel regulatory pathway • • Large & complex clinical / Bio-studies High technology barrier in development & manufacturing Fast-following on potential OTC switches 18

View entire presentation